Molecular and cellular effects of methotrexate

Current Opinion in Rheumatology

Volumn 11, Issue 3, 1999, Pages 226-232

  Seitz, Michael ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; METHOTREXATE;

ANTIINFLAMMATORY ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; HUMAN; INFLAMMATORY CELL; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ADENOSINE; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; METHOTREXATE; METHYLATION;

EID: 0032998815     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199905000-00012     Document Type: Review

References (86)

1. 1 Allegra CJ, Drake JC, Jolivet J, et al: Inhition of phosphoribosylaminoimidazolcarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985, 82:4881-4885.
2. 2 Bagott JE, Vaughan WH, Hudson BB: Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adeny-late deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986, 236:193-200.
3. 3 Gruber HE, Hoffer ME, McAllister DR, et al: Increased adenosine concentration in blood from ischemic myocardium by AICA-riboside: effects on flow, granulocytes and injury. Circulation 1989, 80:1400-1411.
4. 4 Barankiewicz J, Ranlov G, Jimenez R, et al: Selective adenosine release from human B but not T lymphoid cell line. J Biol Chem 1990, 265:15738-15743.
5. 5 Ha T, Morgan SL, Vaughan WH, et al: Inhibition of adenosine deaminase and 5-adenosyl homocysteine hydrolase by 5-aminoimidazole-4-carboxamide riboside. FASEB J 1992, 6:1210-1215.
6. 6 Morabito L, Montesinos MC, Schreibman DM, et al: Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998, 101:295-300.
7. 7 Cronstein BN, Kramer SB, Weissmann G, et al: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991, 88:2441-2445.
8. 8 Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vitro model of inflammation. J Clin Invest 1993, 92:2675-2682.
9. 9 Cronstein BN, Kramer SB, Weissmann G, et al: Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983, 158:1160-1177.
10. 10 Cronstein BN, Rosenstein ED, Kramer SB, et al: Adenosine, a physiologic modulator of superoxide anion generation by human neutrophils: adenosine acts via an A2 receptor on human neutrophils. J Immunol 1985, 135:1366-1371.
11. 11 Cronstein BN, Levin RE, Philips MR, et al: Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 1992, 148:2201-2206.
12. 12 Krump E, Lemay G, Borgeat D: Adenosine A2 receptor-induced inhibition of leukotriene B4 synthesis in whole blood ex vivo. Br J Pharmacol 1996, 117:1639-1644.
13. 13 Thiel M, Chouker A: Acting via A2 receptors, adenosine inhibits production of tumor necrosis factor α of endotoxin-stimulated polymorphonuclear leukocytes. J Lab Clin Med 1995, 126:275-282.
14. 14 Sajjadi FG, Takabayashi K, Foster AC, et al: Inhibition of TNFα expression by adenosine: Role of A3 adenosine receptors. J Immunol 1996, 156:3435-3442.
15. 15 Bouma MG, Stad RK, van den Wildenberg FA, et al: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994, 1:4159-4168.
16. 16 Cronstein BN: The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997, 23:739-755.
17. 17 Le Moine O, Stordeur P, Schandene L, et al: Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996, 156:4408-4414.
18. 18 Constantin A, Loubet-Lescoulié P, Lambert N, et al: Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased IL-4 and IL-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 1998, 41:48-57.
19. 19 Bouma MG, van den Wildenberg FA, Buurman WA: Adenosine inhibitis cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 1996, 39:522-529.
20. 20 Cream JJ, Pole DS: The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol 1980, 102:557-563.
21. Dolhain RJ, Tak PP, Dijkmann BA, et al: Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998, 37:502-508.
22. 22 Firestein GS, Paine MM, Boyle DL, et al: Mechanisms of methotrexate action in rheumatoid arthritis: selective decrease in synovial collagenase gene expression. Arthritis Rheum 1994, 37:193-200.
23. 23 Boyle DL, Sajjadi FG, Firestein GS: Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 1996, 39:923-930.
24. 24 Parmely MJ, Zhou WW, Edwards CK, et al: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 1993, 151:389-396.
25. 25 Merrill JT, Shen C, Schreibman D, et al: Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 1997, 40:1308-1315.
26. 26 Pasini FL, Capecchi PL, Di Perri T: Adenosine plasma levels after low dose methotrexate administration [letter to the editor]. J Rheumatol 1997, 24:2492-2493.
27. 27 Bernini JC, Fort DW, Griener JC, et al: Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995, 345:544-547.
28. 28 Seidmann P, Muller-Suur R, Ekman E: Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993, 20:1126-1128.
29. 29 Osswald H, Gleiter C, Muhlbauer B: Therapeutic use of theophylline to antagonize renal effects of adenosine. Clin Nephrol 1995, 1(suppl 43):33-37.
30. 30 Cronstein BN, Naime D, Firestein GS: The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 1995, 38:1040-1045.
31. 31 Firestein GS, Boyle D, Bullowsky DA, et al: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 1994, 152:5853-5859.
32. 32 Rosengren S, Bang BW, Firestein GS: Anti-inflammatory effects of an adenosine kinase inhibitor: decreased neutrophil accumulation and vascular leakage. J Immunol 1995, 154:5444-5451.
33. 33 Gadangi P, Longaker M, Naime D, et al: The antiinflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996, 156:1937-1941.
34. 34 Chabner BA, Allegra A, Curt C, et al: Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 1985, 76:907-912.
35. 35 Scanlan KJ, Berkowitz K, Pallai ME, et al: Inhibition of methionine transport by methotrexate in mitogen stimulated human lymphocytes. Cancer Treat Rep 1983, 67:631-639.
36. 36 Finkelstein JD: Methionine metabolism in mammals. J Nutr Biochem 1990, 1:228-237.
37. 37 Tabor CW, Tabor H: Polyamines. Ann Rev Biochem 1984, 53:749-790,
38. 38 Furumitsu Y, Yukioka K, Kojima A, et al: Levels of urinary polyamines in patients with rheumatoid arthritis. J Rheumatol 1993, 20:1661-1665.
39. 39 Yukioka K, Wakitani S, Yukioka M, et al: Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis. J Rheumatol 1992, 19:689-692.
40. 40 Nesker G, Moore TL: The in vitro effects of methotrexate on peripheral blood mononuclear cells: modulation by methyl donor and spermidine. Arthritis Rheum 1990, 33:954-959.
41. 41 Flescher E, Bowlin TL, Ballester A, et al: Increased polyamines may down-regulate interleukin 2 production in rheumatoid arthritis. J Clin Invest 1989, 83:1356-1362.
42. 42 Flescher E, Bowlin TL, Talal N: Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids. Clin Exp Immunol 1992, 87:435-437.
43. 43 Kremer MJ: The mechanisms of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994, 21:1-5.
44. 44 Alarcon GS, Schrohenloher RE, Bartolucci AA, et al: Suppression of rheumatoid factor production by methotrexate in patients with rheumoid arthritis. Arthritis Rheum 1990, 33:1156-1161.
45. 45 Anderson PA, West SG, O'Dell JR, et al: Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunological effects in a randomized double-blind study. Ann Intern Med 1985, 103:489-496.
46. 46 Calabrese LH, Taylor JV, Wilke WS, et al: Response of immunoregulatory lymphocyte subsets to methotrexate in rheumatoid arthritis. Cleve Clin J Med 1990, 57:232-241.
47. 47 Olsen NJ, Murray LM: Antiproliferate effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989, 32:378-388.
48. 48 Wascher TC, Hermann J, Brezinschek HP, et al: Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Invest 1994, 72:535-540.
49. 49 Segal R, Yaron M, Tartakovsky B, et al: Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990, 20:190-199.
50. 50 Genestier L, Paillot R, Fournel S, et al: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322-328.
51. 51 Kremer JM, Rynes RI, Bartholomew BL: Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy: double-blind study. Am J Med 1987, 82:781-786.
52. 52 Sperling RI, Benincaso AI, Anderson RJ, et al: Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992, 35:370-384.
53. 53 Hawkes JS, Cleland LG, Proudman SM, et al: The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J Rheumatol 1994, 21:55-58.
54. 54 Sperling RI, Coblyn JG, Larkin JK, et al: Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990, 33:1149-1155.
55. 55 Leroux JL, Damon M, Chavis C, et al: Effects of a single dose of methotrexate on 5-and 12-lipoxygenase products in patients with rheumatoid arthritis. J Rheumatol 1992, 19:863-866.
56. 56 Kremer JM, Jubiz W, Michalek A, et al: Fish-oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled, cross-over study. Ann Intern Med 1987, 166:497-503.
57. 57 Kremer JM, Lawrence DA, Jubiz W, et al: Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis: clinical and immunological effects. Arthritis Rheum 1990, 33:810-820.
58. 58 Vergne P, Liagre B, Bertin P, et al: Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. J Rheumatol 1998, 25:433-440.
59. 59 Johnson WJ, DiMartino MJ, Meunier PC, et al: Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arteritis. J Rheumatol 1988, 15:745-749.
60. 60 Hu S-K, Mitcho YL, Oronsky AL, et al: Studies on the effect of methotrexate on macrophage function. J Rheumatol 1988, 15:206-209.
61. 61 Chang D-M, Weinblatt ME, Schur PH: The effects of methotrexate on inferleukin 1 in patients with rheumatoid arthritis. J Rheumatol 1992, 19:1678-1682.
62. 62 Ranjeny T, Carroll GJ: Reduction of leukocyte and interleukin-1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993, 36:1244-1252.
63. 63 Barrera P, Boerbooms AMT, Demacker PNM, et al: Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol 1994, 33:1017-1024.
64. 64 Seitz M, Loetscher P, Dewald B, et al: Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1β and IL-8-markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol 1996, 23:1512-1516.
65. 65 Rordorf-Adam C, Lazdins J, Woods-Cook K, et al: An assay for the detection of interleukin-1 synthesis inhibitors: effects of antirheumatic drugs. Drugs Exp Clin Res 1989, 15:366-372.
66. 66 Danis VA, Franic GM, Brooks PM: The effect of slow-acting anti-rheumatic drugs (SAARDs) and combination of SAARDs on monokine production in vitro. Drugs Exp Clin Res 1991, 17:549-554.
67. 67 Seitz M, Loetscher P, Dewald B, et al: In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. J Rheumatol 1997, 24:1471-1476.
68. 68 Chang DM, Baptiste P, Schur PH: The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol 1990, 17:1148-1157.
69. 69 Segal R, Mozes E, Yaron M, et al: The effects of methotrexate on the production and activity of IL-1. Arthritis Rheum 1989, 32:370-377.
70. 70 Segal R, Yaron M, Tartakovsky B, et al: Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system. Arthritis Rheum 1990, 33:1745-1748.
71. 71 Brody M, Bohm I, Bauer R: Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1β to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 1993, 31:667-674.
72. 72 Seitz M, Loetscher P, Dewald B, et al: Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995, 34:602-609.
73. 73 Seitz M, Zwicker M, Loetscher P: Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum 1998, 41:2032-2038.
74. 74 Williams AS, Camilleri JP, Topley N, et al: Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate. J Pharmacol Toxicol Methods 1994, 32:53-58.
75. 75 Williams AS, Punn YL, Amos N, et al: The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes. Br J Rheumatol 1995, 34:241-245.
76. 76 Williams AS, Topley N, Williams BD: Effect of liposomally encapsulated MTX-DMPE conjugates upon TNFα and PGE2 release by lipopolysaccharide stimulated rat peritoneal macrophages. Biochim Biophys Acta 1994, 1225:217-222.
77. 77 Seitz M, Dewald B, Ceska M, et al: Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol Int 1992, 12:159-164.
78. 78 Hirata S, Matsubara T, Saura R, et al: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989, 32:1065-1073.
79. 79 Billington DC: Angiogenesis and its inhibition: potential new therapies in oncology and non-neopiastic diseases. Drug Des Discov 1991, 8:3-35.
80. 80 Koch AE, Polverini PJ, Kunkel SL, et al: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1898-1901.
81. 81 Barrera P, Boerbooms AM, Sauerwein RW, et al: Interference of circulating azathioprine but not methotrexate or sulfasalazine with measurements of interleukin-6 bioactivity. Lymphokine Cytokine Res 1994, 13:155-159.
82. 82 Barrera P, Boerbooms AMT, Janssen EM, et al: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993, 36:1070-1079.
83. 83 Crilly A, McIness JB, McDonald AG, et al: Interleukin 6 (IL-6) and IL-2 receptor levels in patients with rheumatoid arthritis treated with low-dose oral methotrexate. J Rheumatol 1995, 22:224-226.
84. 84 Lacki JK, Klama K, Mackiewitz SH, et al: Circulating interleukin 10 and interleukin 6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report. Inflammation Res 1995, 44:24-26.
85. 85 Wascher TC, Hermann J, Brezineschek R, et al: Serum levels of interleukin-6 and tumor-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate. Eur J Clin Invest 1994, 24:73-75.
86. 86 Seitz M, Dayer J-M: Stimulation of TIMP-1 production in patients with rheumatoid arthritis upon MTX treatment [abstract]. Z Rheumatol 1998, 57(suppl 1):P122.